Navigation Links
Pharmasset Reports Fiscal Year End 2008 Financial Results
Date:12/11/2008

aive and treatment experienced HCV patients. In addition, the company was issued a US patent covering R7128.

Results from the 28 day study were presented at the recent American Association for the Study of Liver Diseases (AASLD) that demonstrated that R7128 combined with the standard of care (pegylated interferon and ribavirin) provided significant short-term antiviral activity with safety and tolerability comparable to the standard of care alone. Results from the 500mg BID, 1000mg BID, 1500mg BID dose cohorts in 81 treatment-naive patients chronically infected with HCV genotype 1 indicated rapid virological response (RVR) rates of 30% (6 of 20), 88% (22 of 25) and 85% (17 of 20), respectively compared to 19% (3 of 16) in the control group. Further results in genotype 2 and 3, non responder patients treated with 1500mg BID generated RVR rate of 90% (18 of 20) versus 60% (3 of 5) in the control group. Across all studies, safety and tolerability of R7128 combined with peginterferon and ribavirin was similar to the standard of care alone.

Based on these results and other data, Pharmasset's partner, Roche, plans to move R7128 into a phase 2b trial in HCV-1 infected patients in the first calendar quarter of 2009. Pharmasset has submitted the necessary briefing documents to the FDA and both Roche and Pharmasset plan to meet with the agency in early January to review the preclinical and clinical data and to discuss the phase 2b design and future studies.

In addition to planning for phase 2b, Roche initiated the INFORM-1 trial, a potentially ground-breaking study to investigate the activity of a combination of two oral antiviral molecules in the absence of interferon. The study began in November 2008, and will investigate the combination of Pharmasset's R7128 with InterMune's R7227, a protease inhibitor. The first cohort of patients has been enrolled and preliminary results from this study are expected in fi
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
2. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
3. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
4. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
5. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
6. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
7. Pharmasset Receives Notice of Allowance
8. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
11. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014 AFFiRiS ... New York results of AFF008, a Phase I ... is the first therapy against the protein alpha-synuclein, a promising ... Michael J. Fox Foundation for Parkinson,s Research (MJFF) supported the ... the press conference on the impact a disease-modifying therapy would ...
(Date:7/31/2014)... and LONDON , July 31, 2014 /PRNewswire/ ... services provider for the medical industries, announced today the incorporation of ... United Kingdom has one of the largest ... 8.9 billion in 2012 and it is projected to increase by ... USD 234 billion in 2012, equal to 9.5% of GDP. Despite ...
(Date:7/31/2014)... , July 31, 2014 Vermillion, Inc. (NASDAQ: ... women,s health, will hold a conference call on Thursday, August ... for the second quarter ended June 30, 2014. Financial results ... call. Vermillion,s Chairman, President and CEO James ... and answer period. Date: Thursday, August 14, 2014 ...
Breaking Medicine Technology:First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4genae Opens Offices in London 2Vermillion Sets Second Quarter 2014 Conference Call for Thursday, August 14, 2014 2
... 02, 2007 /PRNewswire-FirstCall/ - YM,BioSciences Inc. ... develops,and commercializes differentiated products for patients ... randomized,placebo-controlled Phase IIb trial of AeroLEF(TM) ... following orthopedic surgery.,AeroLEF(TM) met the primary ...
... 2, 2007 - Acorda Therapeutics, Inc.(R),(Nasdaq: ACOR) ... clinical trial,of Fampridine-SR in people with multiple ... meeting. Andrew Goodman, M.D.,Director of the Multiple ... top-line results on walking ability, leg,strength, spasticity ...
Cached Medicine Technology:YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets,Primary Endpoint in Patients with Post-Surgical Pain 2YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets,Primary Endpoint in Patients with Post-Surgical Pain 3Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 2Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 3Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 4Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 5Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 6Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 7
(Date:7/31/2014)... Andrie, Inc. V. Dept. of Treasury, Mich. ... Court has made the determination that a purchaser of tangible ... taxpayer was unable to prove during an audit that ... the Court of Appeals decision on whether a purchaser bears ... for purchases from Michigan sellers. The Court states “in order ...
(Date:7/31/2014)... Miami, FL (PRWEB) July 31, 2014 ... recently released their innovative compression elbow sleeve , ... other elbow pain, in two new bright colors for ... neon pink and blue. Made of innovative proprietary Zensah® ... moisture wicking and odor-preventing fabric. It features a no-slip ...
(Date:7/31/2014)... 2014 Parker Waichman, LLP, a national ... comments that whistleblowers are a critical component of the ... that may cause harm to consumers and may defraud ... Appreciation Day. , According to a 2013 report issued ... declared "National Whistleblower Appreciation Day" on July 30, 2013; ...
(Date:7/31/2014)... 31, 2014 CarePoint Health is ... Masood Rizvi, has joined our network, CarePoint Health ... the community. Hundreds of highly skilled and experienced ... network of top doctors and practices in Hudson ... latest acquisition represents CarePoint Health’s commitment to provide ...
(Date:7/31/2014)... CT (PRWEB) July 31, 2014 You’re having ... So why have you suddenly developed chills and fever, headache, ... If you suspect a flu-like illness, it could actually be ... , Your risk of developing Lyme is greater than you ... 30,000 new cases occurred in the U.S. annually. But the ...
Breaking Medicine News(10 mins):Health News:Taxpayer Failing To Prove Sales Tax Was Paid At Time Of Purchase Results In Use Tax Due 2Health News:Taxpayer Failing To Prove Sales Tax Was Paid At Time Of Purchase Results In Use Tax Due 3Health News:Compression Elbow Sleeve Provides Relief From Elbow Pain to Golfers and Tennis Players 2Health News:Compression Elbow Sleeve Provides Relief From Elbow Pain to Golfers and Tennis Players 3Health News:National Whistleblower Appreciation Day Declared to Ensure Recognition of Enormous Contribution to the Democracy by Whistleblowers, Parker Waichman LLP Comments 2Health News:National Whistleblower Appreciation Day Declared to Ensure Recognition of Enormous Contribution to the Democracy by Whistleblowers, Parker Waichman LLP Comments 3Health News:National Whistleblower Appreciation Day Declared to Ensure Recognition of Enormous Contribution to the Democracy by Whistleblowers, Parker Waichman LLP Comments 4Health News:Dr. Rizvi Joins CarePoint Health Medical Group 2Health News:Feel Like You Have A Summertime 'Flu'? It Could Be Lyme Disease 2Health News:Feel Like You Have A Summertime 'Flu'? It Could Be Lyme Disease 3
... equal for both procedures , , FRIDAY, May 16 ... for colon cancer produce similar outcomes, according to researchers ... 3,300 patients. , "For a long time, many ... in colorectal cancer patients and cause metastases in the ...
... ,Click It or Ticket ... Local high schoolers display art and videos promoting seat belt use, CLEVELAND, May ... mobilization, When: Monday, May 19, 2008 ... 11:30 AM), Where: The Cleveland House of Blues ...
... of CSL Behring, maker of Zemaira(R), Alpha-1 Proteinase Inhibitor (Human) ... ... PRUSSIA, Pa., May 17 Melissa Biggs, a fashion,designer and actress who ... of CSL Behring, and is,urging Americans to get tested for alpha-1 antitrypsin ...
... & Back; Merger Sets Up Healthy ... Back Retail Chain, LORTON, Va., May 16 ... and workplace back wellness created an,ergonomic revolution, has acquired ... Healthy Back,s 18 stores and ecommerce division,claimed 2007 revenues ...
... There,s more to a healthy mouth than,flashing a ... America,s oral care,habits - and what it means ... report from Oral Health America & Philips Sonicare ... video, audio, text, graphics and,photos for free and ...
... report side effects, but critics want agency to act, ... -- Direct-to-consumer drug ads on television should include a ... adverse side effects, U.S. health experts suggested Friday. , ... U.S. Food and Drug Administration. Such phone numbers are ...
Cached Medicine News:Health News:Outcomes Similar for Laparoscopic, Open Colon Cancer Surgeries 2Health News:Northeast Ohio Kicks Off the 2008 Click It or Ticket Campaign 2Health News:Northeast Ohio Kicks Off the 2008 Click It or Ticket Campaign 3Health News:Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease 2Health News:Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease 3Health News:Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease 4Health News:Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease 5Health News:The Back Wars Come to a Close 2Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 2Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 3
Gills Colibri forceps, very fine pointed tips....
Bechert-McPherson tying forceps, angled, 10 mm tying platforms....
Girard angled tying forceps made of titanium has angled 45 shafts with 4 mm tying platforms, width of shafts 0,25 mm, TCI platforms, round handle, diam. 6 mm, overall length 102 mm....
McPherson curved tying forceps made of titanium has curved shafts with 8 mm tying platforms, width of shafts 0,25 mm, TCI platforms, flat handle, width 6 mm, overall length 85 mm....
Medicine Products: